JP2021505526A5 - - Google Patents

Download PDF

Info

Publication number
JP2021505526A5
JP2021505526A5 JP2020521320A JP2020521320A JP2021505526A5 JP 2021505526 A5 JP2021505526 A5 JP 2021505526A5 JP 2020521320 A JP2020521320 A JP 2020521320A JP 2020521320 A JP2020521320 A JP 2020521320A JP 2021505526 A5 JP2021505526 A5 JP 2021505526A5
Authority
JP
Japan
Prior art keywords
cancer
use according
inhibitor
combination
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020521320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505526A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058277 external-priority patent/WO2019089641A1/en
Publication of JP2021505526A publication Critical patent/JP2021505526A/ja
Publication of JP2021505526A5 publication Critical patent/JP2021505526A5/ja
Priority to JP2023082991A priority Critical patent/JP2023109899A/ja
Pending legal-status Critical Current

Links

JP2020521320A 2017-10-31 2018-10-30 少なくとも1つのスプライソソームモジュレーターと、bcl2阻害剤、bcl2/bclxl阻害剤及びbclxl阻害剤から選択される少なくとも1つの阻害剤とを含む組合せ、並びに使用の方法 Pending JP2021505526A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023082991A JP2023109899A (ja) 2017-10-31 2023-05-19 少なくとも1つのスプライソソームモジュレーターと、bcl2阻害剤、bcl2/bclxl阻害剤及びbclxl阻害剤から選択される少なくとも1つの阻害剤とを含む組合せ、並びに使用の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762579666P 2017-10-31 2017-10-31
US62/579,666 2017-10-31
US201762580364P 2017-11-01 2017-11-01
US62/580,364 2017-11-01
PCT/US2018/058277 WO2019089641A1 (en) 2017-10-31 2018-10-30 Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023082991A Division JP2023109899A (ja) 2017-10-31 2023-05-19 少なくとも1つのスプライソソームモジュレーターと、bcl2阻害剤、bcl2/bclxl阻害剤及びbclxl阻害剤から選択される少なくとも1つの阻害剤とを含む組合せ、並びに使用の方法

Publications (2)

Publication Number Publication Date
JP2021505526A JP2021505526A (ja) 2021-02-18
JP2021505526A5 true JP2021505526A5 (cg-RX-API-DMAC7.html) 2021-12-02

Family

ID=64277937

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020521320A Pending JP2021505526A (ja) 2017-10-31 2018-10-30 少なくとも1つのスプライソソームモジュレーターと、bcl2阻害剤、bcl2/bclxl阻害剤及びbclxl阻害剤から選択される少なくとも1つの阻害剤とを含む組合せ、並びに使用の方法
JP2023082991A Pending JP2023109899A (ja) 2017-10-31 2023-05-19 少なくとも1つのスプライソソームモジュレーターと、bcl2阻害剤、bcl2/bclxl阻害剤及びbclxl阻害剤から選択される少なくとも1つの阻害剤とを含む組合せ、並びに使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023082991A Pending JP2023109899A (ja) 2017-10-31 2023-05-19 少なくとも1つのスプライソソームモジュレーターと、bcl2阻害剤、bcl2/bclxl阻害剤及びbclxl阻害剤から選択される少なくとも1つの阻害剤とを含む組合せ、並びに使用の方法

Country Status (12)

Country Link
US (1) US11524009B2 (cg-RX-API-DMAC7.html)
EP (1) EP3703755B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021505526A (cg-RX-API-DMAC7.html)
KR (1) KR20200083532A (cg-RX-API-DMAC7.html)
CN (1) CN111727059A (cg-RX-API-DMAC7.html)
AU (1) AU2018360559B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008362A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079089A1 (cg-RX-API-DMAC7.html)
IL (1) IL274150A (cg-RX-API-DMAC7.html)
MX (1) MX2020004179A (cg-RX-API-DMAC7.html)
SG (1) SG11202003197TA (cg-RX-API-DMAC7.html)
WO (1) WO2019089641A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
EP4051286A1 (en) * 2019-10-29 2022-09-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating uveal melanoma
EP4161966A1 (en) * 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
ES2919898B8 (es) * 2021-01-27 2024-02-02 Fundacion Univ San Antonio Nuevo tratamiento del cáncer colorrectal
CN112691195B (zh) * 2021-02-02 2023-03-14 黑龙江省科学院高技术研究院 Prpf8表达抑制剂在制备治疗肺癌的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
US7576204B2 (en) 2002-07-31 2009-08-18 Mercian Corporation Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
RU2338741C2 (ru) 2002-07-31 2008-11-20 Мершан Корпорейшн Новые физиологически активные вещества
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
RU2330069C2 (ru) 2002-11-29 2008-07-27 Мершан Корпорейшн Способ получения макролидного соединения и штаммы streptomyces sp., mortierella sp. и micromonosporaceae
CN1886505A (zh) 2003-11-27 2006-12-27 美露香株式会社 参与大环内酯类化合物的羟化作用的dna
CN1977046A (zh) 2004-07-20 2007-06-06 卫材R&D管理有限公司 编码参与普拉地内酯生物合成的多肽的dna
EP1792622A1 (en) * 2005-11-11 2007-06-06 GPC Biotech AG Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and EGFR inhibitors or pyrimidine analogues
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014089571A1 (en) * 2012-12-09 2014-06-12 St. Jude Children's Research Hospital Anticancer compounds
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
MX371455B (es) 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
RS58400B1 (sr) * 2014-05-15 2019-04-30 Eisai R&D Man Co Ltd Jedinjenja pladienolid piridina i postupci primene
IL295472B2 (en) * 2016-03-28 2024-10-01 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer

Similar Documents

Publication Publication Date Title
Seo et al. The role of epithelial–mesenchymal transition-regulating transcription factors in anti-cancer drug resistance
JP2022515197A5 (cg-RX-API-DMAC7.html)
DK3197456T3 (en) CANCER TREATMENTS
CY1118191T1 (el) Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης
JP2022544280A5 (cg-RX-API-DMAC7.html)
JP2021080296A5 (cg-RX-API-DMAC7.html)
JP2016512230A5 (cg-RX-API-DMAC7.html)
JP2010270124A5 (cg-RX-API-DMAC7.html)
RU2016148887A (ru) Пиридиновые соединения пладиенолида и способы применения
JP2013518107A5 (cg-RX-API-DMAC7.html)
CY1108324T1 (el) Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης
JP2016519069A5 (cg-RX-API-DMAC7.html)
JP2016224056A5 (cg-RX-API-DMAC7.html)
RU2009146008A (ru) Синергическая фармацевтическая комбинация для лечения рака
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
JP2003306481A5 (cg-RX-API-DMAC7.html)
JP2016520057A5 (cg-RX-API-DMAC7.html)
JP2017533220A5 (cg-RX-API-DMAC7.html)
Selvaggi et al. Wingless/It/β-catenin signaling in liver metastasis from colorectal cancer: A focus on biological mechanisms and therapeutic opportunities
JP2019038796A5 (cg-RX-API-DMAC7.html)
JP2016517401A5 (cg-RX-API-DMAC7.html)
JP2019507764A5 (cg-RX-API-DMAC7.html)
JP2023553533A5 (cg-RX-API-DMAC7.html)
JP2015507020A5 (cg-RX-API-DMAC7.html)
JP2023526517A5 (cg-RX-API-DMAC7.html)